NASDAQ:CMPS

COMPASS Pathways (CMPS) Stock Forecast, Price & News

$7.88

+0.29 (+3.82%)

(As of 06/2/2023 ET)

Compare

Today's Range: $7.60
▼
$7.97
50-Day Range: $7.34
▼
$10.69
52-Week Range: $6.97
▼
$21.50

Volume: 173,863 shs
Average Volume: 171,802 shs
Market Capitalization: $335.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.83

COMPASS Pathways MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 496.4% Upside
$47.00 Price Target
Short Interest: Bearish
6.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.63
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.60) to ($2.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

821st out of 983 stocks

Pharmaceutical Preparations Industry

414th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
COMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.00, COMPASS Pathways has a forecasted upside of 496.4% from its current price of $7.88.
Amount of Analyst Coverage
COMPASS Pathways has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.40% of the outstanding shares of COMPASS Pathways have been sold short.
Short Interest Ratio / Days to Cover
COMPASS Pathways has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
Change versus previous month
Short interest in COMPASS Pathways has recently decreased by 0.36%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
COMPASS Pathways does not currently pay a dividend.
Dividend Growth
COMPASS Pathways does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMPS.

2.0

News and Social Media Coverage

News Sentiment
COMPASS Pathways has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 11 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, COMPASS Pathways insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.85% of the stock of COMPASS Pathways is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.54% of the stock of COMPASS Pathways is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.60) to ($2.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of COMPASS Pathways is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of COMPASS Pathways is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
COMPASS Pathways has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About COMPASS Pathways (NASDAQ:CMPS) Stock

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

CMPS Stock News Headlines

May 31, 2023 | finance.yahoo.com

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

May 30, 2023 | markets.businessinsider.com

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 28, 2023 | benzinga.com

Compass Pathways Stock (NASDAQ:CMPS), Insider Trading Activity

May 26, 2023 | markets.businessinsider.com

Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session

May 26, 2023 | finance.yahoo.com

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

May 26, 2023 | finance.yahoo.com

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

May 17, 2023 | americanbankingnews.com

COMPASS Pathways plc (NASDAQ:CMPS) Forecasted to Earn Q2 2023 Earnings of ($0.74) Per Share

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (ZYNE) and COMPASS Pathways (CMPS)

May 13, 2023 | markets.businessinsider.com

COMPASS Pathways (CMPS) Gets a Buy from Maxim Group

May 11, 2023 | markets.businessinsider.com

Expert Ratings for Compass Pathways

May 11, 2023 | finance.yahoo.com

Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript

May 11, 2023 | finance.yahoo.com

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

May 10, 2023 | msn.com

COMPASS Pathways ADS Q1 2023 Earnings Preview

May 10, 2023 | americanbankingnews.com

COMPASS Pathways (CMPS) to Release Earnings on Thursday

May 8, 2023 | msn.com

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More

May 6, 2023 | finance.yahoo.com

This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why

May 3, 2023 | finance.yahoo.com

COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

May 2, 2023 | msn.com

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

May 2, 2023 | finance.yahoo.com

American Medical Association to Issue First New Code for Psychedelic Therapies

April 21, 2023 | marketwatch.com

8-K: COMPASS Pathways plc

April 20, 2023 | finance.yahoo.com

After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?

April 15, 2023 | americanbankingnews.com

EF Hutton Acquisition Co. I Reaffirms Buy Rating for COMPASS Pathways (NASDAQ:CMPS)

April 13, 2023 | msn.com

EF Hutton Reiterates COMPASS Pathways Plc American Depository Shares (CMPS) Buy Recommendation

April 12, 2023 | seekingalpha.com

COMPASS Pathways: Cash Burn Rate Overshadows Positive Trial Progress

April 12, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS)

See More Headlines

CMPS Price History

30 days | 90 days | 365 days | Advanced Chart

CMPS Company Calendar

Last Earnings: 11/08/2021
Today: 6/03/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CMPS
CUSIP: N/A
CIK: 1816590
Web: www.compasspathways.com
Phone: 716-676-6461
Fax: N/A
Employees: 116
Year Founded: 2016

Price Target and Rating

Average Stock Price Forecast: $47.00
High Stock Price Forecast: $120.00
Low Stock Price Forecast: $19.00
Forecasted Upside/Downside: +342.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,500,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.62%
Return on Assets: -45.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.91
Quick Ratio: 14.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.79 per share
Price / Book: 2.08

Miscellaneous

Outstanding Shares: 42,630,000
Free Float: 32,038,000
Market Cap: $335.92 million
Optionable: Not Optionable
Beta: 2.50

Social Links

Key Executives

Mr. George Jay Goldsmith (Age 68)
Exec. Chairman & Co-Founder
Comp: $943.52k

Dr. Ekaterina Malievskaia M.D. (Age 55)
Co-Founder, Chief Innovation Officer & Exec. Director
Comp: $669.13k

Dr. Guy Goodwin
Chief Medical Officer

Mr. Kabir Nath M.A.
M.B.A., Chief Exec. Officer

Mr. Michael F. Falvey (Age 63)
Chief Financial Officer

Dr. Greg Ryslik Ph.D.
Exec. VP of AI, Engineering, Digital Health Research & Technology

Mr. Stephen D. Schultz
Sr. VP of Investor Relations

Mr. Matthew Owens
Gen. Counsel & Chief Legal Officer

Mr. Christopher Williams
Chief Communications Officer

Ms. Anne Benedict
Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CMPS Stock - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings or view top-rated stocks.
What is COMPASS Pathways' stock price forecast for 2023?: 5 equities research analysts have issued twelve-month price objectives for COMPASS Pathways' stock. Their CMPS share price forecasts range from $19.00 to $120.00. On average, they predict the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 496.4% from the stock's current price.
View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts.
How have CMPS shares performed in 2023?: COMPASS Pathways' stock was trading at $8.03 at the start of the year. Since then, CMPS stock has decreased by 1.9% and is now trading at $7.88.
View the best growth stocks for 2023 here.
When is COMPASS Pathways' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CMPS earnings forecast.
How were COMPASS Pathways' earnings last quarter?: COMPASS Pathways plc (NASDAQ:CMPS) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11.
What ETFs hold COMPASS Pathways' stock?: ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), ARK Genomic Revolution ETF (ARKG), Subversive Mental Health ETF (SANE), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Putnam Sustainable Future ETF (PFUT), Grizzle Growth ETF (GRZZ), ALPS Medical Breakthroughs ETF (SBIO) and iShares Biotechnology ETF (IBB).
What other stocks do shareholders of COMPASS Pathways own?: Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?: (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is COMPASS Pathways' stock symbol?: COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."
Who are COMPASS Pathways' major shareholders?: COMPASS Pathways' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (5.96%), Sumitomo Mitsui Trust Holdings Inc. (0.91%), Nikko Asset Management Americas Inc. (0.91%), Barclays PLC (0.80%), BlackRock Inc. (0.62%) and Putnam Investments LLC (0.57%). Insiders that own company stock include David Y Norton and Ekaterina Malievskaia.
View institutional ownership trends.
How do I buy shares of COMPASS Pathways?: Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is COMPASS Pathways' stock price today?: One share of CMPS stock can currently be purchased for approximately $7.88.
How much money does COMPASS Pathways make?: COMPASS Pathways (NASDAQ:CMPS) has a market capitalization of $335.92 million. The company earns $-91,500,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.
How many employees does COMPASS Pathways have?: The company employs 116 workers across the globe.
How can I contact COMPASS Pathways?: The official website for the company is www.compasspathways.com. The company can be reached via phone at 716-676-6461 or via email at ir@compasspathways.com.

This page (NASDAQ:CMPS) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial